The US Food and Drug Administration approval has been granted to the firm's subsidiary Zydus Cadila, for Losartan Potassium tablets in the strengths of 25 mg, 50 mg and 100 mg and for Losartan Potassium and Hydrochlorothiazide tablets in the strengths of 50/ 12.5 mg and 100/25 mg, the company said in a filing to the Bombay Stock Exchange.
The company has already launched both products in the US market.
The drugs, which fall in the anti-hypertensive segment have estimated market sales of USD 1.3 billion and USD 944 million, respectively in 2010, said Cadila Healthcare, quoting healthcare information solutions company NDC Health.
The group has 56 approvals and has filed for 113 Abbreviated New Drug Applications (ANDA's).
Shares of Cadila Healthcare were trading at Rs 694.00 in the afternoon trade on the BSE up 0.08 per cent from its previous close.